Pharmaceutical

BioVersys and Shionogi agree to develop ansamycin leads

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads.

Jul 5, 2025 - 06:00
BioVersys and Shionogi agree to develop ansamycin leads
BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads.
Read the original article

Tags:

Previous Article

UK Government reveals 10-year plan for NHS

Next Article

Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Texas Medicaid agrees to fully cover gene therapy for Afghan refugees’ infant

Texas Medicaid agrees to fully cover gene therapy for A...

Feb 5, 2024

STAT+: NIH grant recipients often fail to disclose agency support in patent applications

STAT+: NIH grant recipients often fail to disclose agen...

May 5, 2023

Interview: Dr Alan S Louie – US Food and Drug Administration Delays

Interview: Dr Alan S Louie – US Food and Drug Administr...

Apr 16, 2023